BRAF and plasma cell myeloma: Since then, three additional cases of refractory myeloma with BRAF V600E mutation being treated with vemurafenib have been reported.9, 10 Two patients had short durations of response, whereas the third still had ongoing response 4 months after initiation of therapy.